title: Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases.
abstract: Tissue Factor Pathway Inhibitor (TFPI) prevents further participation of Tissue Factor (TF) in the coagulation process by forming a stable quaternary complex of TF-FVIIa-FXa-TFPI. Recently, plasma TFPI level were found to be elevated in patients with malignant disease outside the brain. Therefore the aim of this study was to investigate the TFPI plasma level in patients with primary brain tumors and intracerebral metastases. From May 2000 to December 2001 the total tissue factor pathway inhibitor antigen (TFPI) was preoperatively determined in blood samples of 225 patients with primary or metastatic brain tumors. Tumor histology classified as benign (WHO grade I and II) and malignant (WHO grade III and IV, intracerebral metastases) was correlated to plasma TFPI-levels. Plasma TFPI was significantly higher in patients with malignant tumors including intracerebral metastasis compared to benign tumors (80.1 +/- 34.31 versus 64.3 +/- 25.8 ng ml-1 [p < 0.01; t-test]). To exclude the influence of primary systemic neoplasms with secondary brain metastasis on plasma TFPI-level a subgroup of patients with primary brain tumors (meningioma, astrocytoma, oligodendroglioma and glioblastoma) was separated. In this group TFPI-level was also significantly elevated in patients with malignant (n = 66) (78.6 +/- 29.9) compared to benign brain tumors (n = 127) (64.3 +/- 25.8 ng ml-1 [p < 0.01; t-test]). To the authors' knowledge this is the first study describing the correlation of increased plasma TFPI and malignancy in patient with brain tumors. Further studies are needed to clarify the pathogenic mechanism and the clinical relevance of this phenomenon.
authors.affiliation: Department of Neurosurgery, Johann Wolfgang Goethe-University, Schleusenweg 2-16, 60528 Frankfurt/Main, Germany. r.gerlach@em.uni-frankfurt.de
authors.forename: Rüdiger
authors.initials: R
authors.lastname: Gerlach
authors.forename: Timm
authors.initials: T
authors.lastname: Scheuer
authors.forename: Martina
authors.initials: M
authors.lastname: Böhm
authors.forename: Jürgen
authors.initials: J
authors.lastname: Beck
authors.forename: Alina
authors.initials: A
authors.lastname: Woszczyk
authors.forename: Andreas
authors.initials: A
authors.lastname: Raabe
authors.forename: Inge
authors.initials: I
authors.lastname: Scharrer
authors.forename: Volker
authors.initials: V
authors.lastname: Seifert
mesh_terms: D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000097:blood / Q000556:secondary; D001932:Brain Neoplasms / Q000097:blood* / Q000473:pathology*; D005260:Female; D005909:Glioblastoma / Q000097:blood* / Q000556:secondary*; D018325:Hemangioblastoma / Q000097:blood / Q000556:secondary; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008577:Meningeal Neoplasms / Q000097:blood / Q000556:secondary; D008579:Meningioma / Q000097:blood / Q000556:secondary; D008875:Middle Aged; D009442:Neurilemmoma / Q000097:blood / Q000556:secondary; D009837:Oligodendroglioma / Q000097:blood / Q000556:secondary; D010911:Pituitary Neoplasms / Q000097:blood / Q000556:secondary
chemical_list: D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor